HFS
CYTK icon

Hantz Financial Services’s Cytokinetics CYTK Stock Holding History

Hantz Financial Services’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$857K Buy
10,063
+3,090
+44% +$222K 0.01% 559
2026
Q1 		$460K Buy
6,973
+129
+2% +$8.2K 0.01% 664
2025
Q4 		$435K Buy
6,844
+2,231
+48% +$139K 0.01% 631
2025
Q3 		$254K Buy
4,613
+3,305
+253% +$136K ﹤0.01% 682
2025
Q2 		$43K Buy
1,308
+1,264
+2,873% +$44K ﹤0.01% 1007
2025
Q1 		$2K Buy
+44
New +$2.02K ﹤0.01% 1353

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hantz Financial Services's CYTK Position: Q2 2026 in Review

Hantz Financial Services increased its Cytokinetics (CYTK) stake by 44% in Q2 2026, buying an estimated $222K and bringing the position to 10,063 shares worth $857K. The position accounts for 0.01% of the portfolio, ranked #559.

Hantz Financial Services first reported a position in CYTK in Q1 2025 and has held it in 6 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Hantz Financial Services held 10,063 shares of Cytokinetics worth $857K as of Q2 2026.
  • Hantz Financial Services bought 3,090 Cytokinetics shares in Q2 2026, an estimated $222K.
  • Cytokinetics made up 0.01% of Hantz Financial Services's portfolio in Q2 2026, its #559 holding.
  • Hantz Financial Services first reported a position in Cytokinetics in Q1 2025 and has held it in 6 quarters since.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.